Danaher's unbroken four-quarter earnings beat streak and 124% free-cash-flow conversion attest to strong fundamental quality; the stock is just below its analyst-derived target with approximately 20% upside and a 3.25-to-1 risk/reward, though the confirmed long-term downtrend below the 200-day moving average and an RSI at overbought levels warrant caution about near-term entry timing.
Thesis pillars
- Perfect Four Quarter Beat Streak↑Improving
- Exceptional Fcf Conversion Quality→Stable
- Confirmed Long Term Downtrend↑Improving
- +1 more pillar — see the Why tab for full reasoning
Danaher Corporation (DHR) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $218.85, but acceptable to hold if already in. Reason: Analyst target reached - limited upside remaining.
Danaher develops instruments, consumables, and services for the biotechnology, life sciences, and diagnostics sectors across approximately 50 countries, organized in three segments under those names. Revenue skews toward recurring consumables and services, with approximately 59%... Read more
Hold if already holding. Not a fresh buy at $218.85, but acceptable to hold if already in. Reason: Analyst target reached - limited upside remaining. Chart setup: Death cross but MACD improving, RSI 73. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-08-24Recent Developments — Danaher Corporation
Latest news
- NEWS Danaher (DHR) Downgraded by Citigroup -- Price Target Lowered to $95 - GuruFocus — GuruFocus negative
- NEWS Danaher (DHR) Receives Buy Rating from Citi with $230 Price Targ - GuruFocus — GuruFocus positive
- NEWS Danaher Corporation Shs Cert Deposito Arg Repr 0.018518518 Sh Balance Sheet – BCBA:DHR.CI - TradingView — TradingView neutral
- NEWS Danaher Corporation (DHR) technical analysis - Danaher (NYSE:DHR) - Benzinga — Benzinga neutral
- NEWS Danaher’s Q2 Earnings Call Shows Life Sciences at Its Best Quarter in Years - TIKR.com — TIKR.com positive
Generated 2026-08-24T11:22:04Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $218.85, but acceptable to hold if already in. Reason: Analyst target reached - limited upside remaining. Chart setup: Death cross but MACD improving, RSI 73. Maintain position. Not compelling to add more. Target $251.68 (+15.0%), stop $205.61 (−6.4%), A.R:R -0.5:1. Score 5.9/10, moderate confidence.
Take-profit target: $251.68 (-6.3% upside). Target $251.68 (+15.0%), stop $205.61 (−6.4%), A.R:R -0.5:1. Stop-loss: $205.61.
Analyst target reached - limited upside remaining.
Danaher Corporation trades at a P/E of 39.1 (forward 23.5). TrendMatrix value score: 4.2/10. Verdict: Hold.
32 analysts cover DHR with a consensus score of 4.2/5. Average price target: $228.
What does Danaher Corporation do?Danaher develops instruments, consumables, and services for the biotechnology, life sciences, and diagnostics sectors...
Danaher develops instruments, consumables, and services for the biotechnology, life sciences, and diagnostics sectors across approximately 50 countries, organized in three segments under those names. Revenue skews toward recurring consumables and services, with approximately 59% of 2025 sales from non-US customers; the company employs approximately 60,000 people across more than 15 operating companies.